急性心肌梗死早期尿激酶静脉溶栓治疗的临床分析

目的探讨尿激酶早期静脉溶栓治疗急性心肌梗死的临床疗效及不良反应。方法2005年2月至2008年8月来我院就诊的急性心肌梗死（AMI）患者80例，经静脉尿激酶（UK）溶栓治疗患者42例，为UK溶栓观察组。同期未溶栓治疗患者38例为未溶栓对照组，除不用尿激酶以外，其余治疗均与UK溶栓组相同。结果UK溶栓观察组冠脉再通率为66．7％，常规对照组为15．8％，UK溶栓观察组4周病死率为4．8％，常规对照组为18．4％，两组差异有统计学意义（P〈0．05）。UK溶栓观察组严重的心律失常率为28．6％，未溶栓对照组为55．3％，两组差异有统计学意义（P〈0．05）。结论急性心肌梗死早期进行尿激酶静脉溶栓治疗可提高AMI血管再通率，降低病死率，减少心力衰竭发生，并发症少，不良反应轻，价格低廉，能提高其生活质量，值得基层医院临床推广。

Clinical analysis of urokinase intravenous thrombolytic therapy for early acute myocardial infarction

Objective To investigate the clinical efficacy and adverse reactions of the urokinase intravenous thrombolysis therapy in treatment of acute myocardial infarction. Methods 80 patients with acute myocardial infarction （AMI） in our hospital from February 2005 to August 2008 were divided into two groups. 42 patients in observe group were received urokinase（UK） intravenously and 38 patients in conventional conrol group were received the same treatment except urokinase thrombolysis,Results The recanalization rate of coronary artery was 66.7% in observes group and 15.8% in conventional control group. The mortality rate in four weeks was 4.8% in observe group and 18.4% in conventional control group. There was significant difference between two groups （P〈 0.05）. The serious arrhythmia rate was 28.6% in observe group and 55.3% in conventional control group, which were also significant different （P〈 0.05）. Conclusion The urokinase intravenous thrombolytic therapy can improve vascular recanalization rate of AMI, lower mortality, reduce the occurrence of heart failure, decrease adverse reactions and improve the quality of life, which is worth promoting among the grass-roots hospital.